Ochratoxin B
(Synonyms: 赭曲霉毒素B) 目录号 : GC40870
Ochratoxin B (OTB)是赭曲霉的次级代谢物，是赭曲霉毒素a (OTA)的非氯化类似物，是啮齿类动物中最有效的肾致癌物之一。
Cas No.:4825-86-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ochratoxin B (OTB), a secondary metabolite of Aspergillus ochraceus, is the nonchlorinated analogue of the mycotoxin ochratoxin A (OTA), which is one of the most potent renal carcinogens in rodents [1].
Intracellular concentration of Ochratoxin B following 24-h incubation with a noncytotoxic dose (10 µM) was 2.2 ± 0.25 pmol/ml of cell lysate for Ochratoxin B [1]. Based on fluorescence studies, Ochratoxin B form highly stable complexes with Human serum albumin (HSA) [2].
The rats given ochratoxin B or ochratoxins A and B (4mg/kg) were clinically unaffected, while the rats given ochratoxin A (4mg/kg) reduced food intake by 50%, and they lost ca. 10% of their weight during the experimental period [3]. Both single (10 mg/kg, oral) and repeated (2 mg/kg 2 weeks, oral) administration of ochratoxin B do not induce pronounced adverse effects in rats as indicated by only minor histopathologic changes in the kidney after a single high dose and absence of histopathology in the kidney and the liver after repeated administration [1].
References:
[1]. Mally A, Keim-Heusler H, Amberg A, et al. Biotransformation and nephrotoxicity of ochratoxin B in rats[J]. Toxicology and applied pharmacology, 2005, 206(1): 43-53.
[2]. Faisal Z, VÖrÖs V, FliszÁr-NyÚl E, et al. Probing the interactions of ochratoxin B, ochratoxin C, patulin, deoxynivalenol, and T-2 toxin with human serum albumin[J]. Toxins, 2020, 12(6): 392.
[3]. StØrmer F C, Kolsaker P, Holm H, et al. Metabolism of ochratoxin B and its possible effects upon the metabolism and toxicity of ochratoxin A in rats[J]. Applied and environmental microbiology, 1985, 49(5): 1108-1112.
| Cell experiment [1]: | |
|
Cell lines |
LLC-PK1 porcine kidney epithelial cells |
|
Preparation Method |
Ochratoxin A and Ochratoxin B were freshly dissolved in ethanol and diluted in medium containing 5% FCS. Cells were seeded in 96-well plates at a density of 1×104 cells/well, allowed to grow for 24 h in ochratoxin-free medium and subsequently incubated with Ochratoxin A or Ochratoxin B at concentrations between 0 and 100 µM for 8, 24 and 72 h. |
|
Reaction Conditions |
0 and 100 µM for 8, 24 and 72 h |
|
Applications |
Cytotoxicity was not observed in LLC-PK1 cells after incubation with Ochratoxin A or Ochratoxin B (up to 100 µM) for 8 h, After 24 h, only minor differences in cytotoxicity were observed between Ochratoxin A and Ochratoxin B. |
| Animal experiment [2]: | |
|
Animal models |
Male F344 Fisher rats |
|
Preparation Method |
Animals (n = 3/group) were treated with a single dose of Ochratoxin B (10 mg/kg bw) in corn oil by oral gavage or repeatedly administered Ochratoxin B (2 mg/kg bw) for 2 weeks (5 days per week). |
|
Dosage form |
10 mg/kg, oral; 2 mg/kg 2 weeks (5 days per week), oral |
|
Applications |
After repeated administration of 2 mg/kg bw/day, no lesions indicative of cytotoxicity was observed in renal tubules and the number of mitotic figures in the proximal tubule epithelium. |
|
References: [1]: Mally A, Keim-Heusler H, Amberg A, et al. Biotransformation and nephrotoxicity of ochratoxin B in rats[J]. Toxicology and applied pharmacology, 2005, 206(1): 43-53. | |
| Cas No. | 4825-86-9 | SDF | |
| 别名 | 赭曲霉毒素B | ||
| 化学名 | N-[[(3R)-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1H-2-benzopyran-7-yl]carbonyl]-L-phenylalanine | ||
| Canonical SMILES | O=C1O[C@@H](C)CC2=C1C(O)=C(C(N[C@H](C(O)=O)CC3=CC=CC=C3)=O)C=C2 | ||
| 分子式 | C20H19NO6 | 分子量 | 369.4 |
| 溶解度 | 50mg/mL in ethanol, 15mg/mL in DMSO, 10mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7071 mL | 13.5355 mL | 27.0709 mL |
| 5 mM | 0.5414 mL | 2.7071 mL | 5.4142 mL |
| 10 mM | 0.2707 mL | 1.3535 mL | 2.7071 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet